Gregory Vite

发表

Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.

J. Fargnoli, S. Sheriff, A. Mathur, 2020, ACS medicinal chemistry letters.

Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs

S. Gygi, B. Cravatt, M. Dix, 2019, Nature Chemistry.

Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs

S. Gygi, B. Cravatt, M. Dix, 2019, Nature Chemistry.

Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.

Vijay T. Ahuja, Derek J. Norris, J. Tokarski, 2021, Journal of medicinal chemistry.

Discovery of Non-Nucleotide Small-Molecule STING Agonists via Chemotype Hybridization.

Alan S. Futran, Vijay T. Ahuja, Shana L. Posy, 2022, Journal of medicinal chemistry.

Preclinical discovery of ixabepilone, a highly active antineoplastic agent

F. Lee, A. Kamath, C. Fairchild, 2008, Cancer Chemotherapy and Pharmacology.

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

F. Lee, C. Fairchild, R. Kramer, 2008, Cancer Chemotherapy and Pharmacology.

Synthesis and Biological Evaluation of a Carbamate-Containing Tubulysin Antibody Drug Conjugate.

P. Cardarelli, Gregory Vite, C. Rao-Naik, 2020, Bioconjugate chemistry.

Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA.

Ping Chen, R. Moquin, J. Tokarski, 2008, Bioorganic & medicinal chemistry letters.

Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.

Murugaiah A. M. Subbaiah, G. Schieven, A. Mathur, 2024, ACS medicinal chemistry letters.

Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology.

G. Schieven, A. Mathur, D. Critton, 2024, ACS medicinal chemistry letters.